TrialLeukemia2011

A phase I/II study of imatinib plus reinduction therapy for c-kit-positive relapsed/refractory acute myeloid leukemia: inhibition of Akt activation correlates with complete response.

J M Brandwein et al.PubMed ↗Publisher ↗

No numbers read from the abstract.